- Home
- RXRX vs SLNO Comparison
RXRX vs SLNO Comparison
Compare RXRX & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXRX | SLNO |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RXRX | SLNO |
|---|---|---|
| Price | $3.47 | $37.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $7.50 | ★ $112.70 |
| AVG Volume (30 Days) | ★ 21.9M | 1.4M |
| Earning Date | 02-27-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $43,689,000.00 | ★ $98,675,000.00 |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | $34.31 | $159.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.45 | $36.89 |
| 52 Week High | $12.36 | $90.32 |
Technical Indicators
Market Signals| Indicator | RXRX | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 35.12 |
| Support Level | $3.54 | $39.23 |
| Resistance Level | $4.09 | $41.84 |
| Average True Range (ATR) | 0.26 | 2.19 |
| MACD | -0.07 | -0.16 |
| Stochastic Oscillator | 3.10 | 4.48 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.